Bo Gamble, Director of Quality and Value - Community Oncology Alliance (COA)
Thanks to advancements of cancer treatments, the cancer death rate has decreased 23% from 1999 to 2019 in the United States. Nevertheless, lung cancer remains the leading cause of cancer death in 2022 in the United States. In patients with non-small cell lung cancer (NSCLC), the 5-year survival ...
*Department of Investigational Cancer Therapeutics
A Case of ST Elevation in a Patient Enrolled in an Anti-CD40 Monoclonal Antibody Phase I Clinical Trial
Proton pump inhibitors (PPI’s) are very common to use in a wide variety of patients to treat many different symptoms of anything from a more serious condition like Barrett’s Esophagus down to a self-diagnosed heartburn. Since they are now over-the-counter, they can be used at any time. Also, ...
Coronaviruses are a large family of viruses that are common in people and animals. SARS-CoV-2, a novel coronavirus, causes a respiratory disease called coronavirus disease 2019, abbreviated COVID-19.1,2 Immunocompromised patients, especially those who have cancer and undergoing treatment, pose to ...
According to the American Cancer Society, between 80 and 100% of patients with cancer report fatigue.1 Fatigue can be present while receiving active anticancer treatment and can persist for as long as 12 months after treatment cessation. In 2000, the National Comprehensive Cancer Network (NCCN) ...
Although treatment strategies for patients with metastatic gastric cancer who have failed prior lines of therapy remain limited, novel agents such as trastuzumab deruxtecan (Enhertu), provide further options for patients with HER2-positive disease.
Beth Sandy, MSN, CRNP
Avani Yenamandra, PharmD
.png?width=40&name=Untitled%20design%20(2).png){kind=avatar}
Christian Watts Pharm.D., MSHI Candidate, Larry Buie Pharm.D., BCOP, FCCP, FASHP, Beth Sandy, MSN, CRNP
Amari Marshall & Abigail Shockley, PharmD
Christina Bartholomew